In patients with chronic hepatitis C (CHC) without cirrhosis, short-duration treatment with glecaprevir/pibrentasvir (G/P) resulted in stable renal function and improvements in cardiovascular (CV) and metabolic extrahepatic manifestation (EHM) markers, especially in those with severe EHMs at baseline. This according to a post-hoc analysis of 2 phase 3 clinical trials in patients without cirrhosis treated with G/P for 8 weeks. In addition, 1 phase 3 trial was carried out to explore the effects of treatment on renal EHMs in patients with advanced renal impairment at baseline. Researchers included all CHC patients treated with G/P for 8 or 12 weeks enrolled across 5, phase 3 trials as a sensitivity analysis. They found:

• G/P treatment for 8 weeks resulted in statistically significant declines in triglycerides (‒28.6 mg/dL) and glucose (‒11.2 mg/dL), with no statistically significant decline in estimated glomerular filtration rate (eGFR).
• Biomarker improvements were greatest among patients with elevated triglycerides and elevated glucose at baseline.
• Similar effects were observed across all patients treated with G/P for 8 or 12 weeks.